Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate Disorders
June 04, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Substantial Treatment Effect Observed in Patients with Enteric Hyperoxaluria, Including Robust Reductions in Both Urine and Plasma Oxalate –-- Reloxaliase Well-Tolerated Over 12 Weeks of Dosing...
Allena Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
May 30, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
May 08, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Entered into Agreement with Duke Clinical Research Institute (DCRI) to Support Phase 3 URIROX-2™ Trial and Promote Enteric Hyperoxaluria Disease Awareness – -- All Clinical Programs Progressing on...
Allena Pharmaceuticals Appoints Allene Diaz to its Board of Directors
April 17, 2019 08:01 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Announces Agreement with Duke Clinical Research Institute for URIROX-2 Pivotal Phase 3 Trial
March 27, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 07, 2019 08:01 ET
|
Allena Pharmaceuticals, Inc.
-- Achieved Alignment with U.S. Food and Drug Administration (FDA) on Phase 3 URIROXTM Program and Accelerated Approval Strategy for Reloxaliase -- -- Phase 3 URIROX-1 and URIROX-2 Trials Ongoing;...
Allena Pharmaceuticals, Inc. to Present at 39th Annual Cowen & Co. Health Care Conference
March 05, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,...
Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019
January 04, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Alexey Margolin, Ph.D. to Transition to Chairman of the Board -- -- URIROX-2™ Initiated; URIROX-1™ Topline Data Expected in Second Half of 2019 -- -- Multiple Catalysts Expected Across Pipeline...
Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria
January 02, 2019 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Primary Efficacy Endpoint of Change in Urinary Oxalate Excretion at Four Weeks -- -- URIROX-2™, Second Pivotal Phase 3 Trial, Initiated in Fourth Quarter of 2018 -- -- URIROX-1™, First Pivotal...
Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
November 07, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Global Phase 3 URIROX-1™ Trial Ongoing; Expect to Initiate Second Phase 3 Study, URIROX-2™, in 2018 -- -- Presented Preclinical Proof-of-Concept Data on ALLN-346 at American College of...